{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:32:16Z","timestamp":1790685136889,"version":"4.1.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.canlet.2020.11.045","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T19:34:00Z","timestamp":1606937640000},"page":"189-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":96,"special_numbering":"C","title":["Hypoxia-mediated drug resistance in breast cancers"],"prefix":"10.1016","volume":"502","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-8663","authenticated-orcid":false,"given":"Courtney E.","family":"McAleese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6768-991X","authenticated-orcid":false,"given":"Chandra","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neville J.","family":"Butcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3178-4835","authenticated-orcid":false,"given":"Rodney F.","family":"Minchin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.canlet.2020.11.045_bib1","doi-asserted-by":"crossref","first-page":"9s","DOI":"10.2967\/jnumed.115.157834","article-title":"Clinical diagnosis and management of breast cancer","volume":"57","author":"McDonald","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.canlet.2020.11.045_bib2","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.canlet.2020.11.045_bib3","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1158\/1078-0432.CCR-05-2690","article-title":"Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer","volume":"12","author":"Generali","year":"2006","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013551","article-title":"Hypoxia-inducible factor 1-alpha expression correlates with response to neoadjuvant chemotherapy in women with breast cancer","volume":"97","author":"Nie","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.canlet.2020.11.045_bib5","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.11.045_bib6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1385\/MO:18:4:243","article-title":"Treatment resistance of solid tumors: role of hypoxia and anemia","volume":"18","author":"Vaupel","year":"2001","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2020.11.045_bib7","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2217\/fon.13.92","article-title":"Role of hypoxia-inducible factors in breast cancer metastasis","volume":"9","author":"Gilkes","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.canlet.2020.11.045_bib8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia \u2014 a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1101\/gad.12.5.607","article-title":"Control of cell lineage-specific development and transcription by bHLH-PAS proteins","volume":"12","author":"Crews","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2020.11.045_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1101\/gad.12.2.149","article-title":"Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha","volume":"12","author":"Iyer","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2020.11.045_bib12","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1101\/gad.12.21.3320","article-title":"The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development","volume":"12","author":"Tian","year":"1998","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2020.11.045_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrc3621","article-title":"bHLH\u2013PAS proteins in cancer","volume":"13","author":"Bersten","year":"2013","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1357-2725(03)00211-5","article-title":"The mammalian basic helix-loop-helix\/PAS family of transcriptional regulators","volume":"36","author":"Kewley","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2020.11.045_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semradonc.2008.12.002","article-title":"Cancer stem cells, hypoxia and metastasis","volume":"19","author":"Hill","year":"2009","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.canlet.2020.11.045_bib16","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1073\/pnas.94.9.4273","article-title":"A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development","volume":"94","author":"Ema","year":"1997","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.11.045_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0925-4773(97)00674-6","article-title":"HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels","volume":"63","author":"Flamme","year":"1997","journal-title":"Mech. Dev."},{"key":"10.1016\/j.canlet.2020.11.045_bib18","first-page":"205","article-title":"Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha","volume":"7","author":"Gu","year":"1998","journal-title":"Gene Expr."},{"key":"10.1016\/j.canlet.2020.11.045_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.11.1.72","article-title":"Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells","volume":"11","author":"Tian","year":"1997","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2020.11.045_bib20","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1146\/annurev.cellbio.15.1.551","article-title":"Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1","volume":"15","author":"Semenza","year":"1999","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2020.11.045_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","article-title":"Hypoxia-inducible factors in physiology and medicine","volume":"148","author":"Semenza","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.11.045_bib22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nrc2540","article-title":"The impact of O2 availability on human cancer","volume":"8","author":"Bertout","year":"2008","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib23","doi-asserted-by":"crossref","first-page":"C260","DOI":"10.1152\/ajpcell.00315.2015","article-title":"Hypoxia-inducible factor 3 biology: complexities and emerging themes","volume":"310","author":"Duan","year":"2016","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.canlet.2020.11.045_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/35107085","article-title":"Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression","volume":"414","author":"Makino","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2020.11.045_bib25","doi-asserted-by":"crossref","first-page":"17771","DOI":"10.1074\/jbc.271.30.17771","article-title":"Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1","volume":"271","author":"Jiang","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.11.045_bib26","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1073\/pnas.140087397","article-title":"The transcription factor EPAS-1\/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling","volume":"97","author":"Peng","year":"2000","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.11.045_bib27","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1073\/pnas.90.9.4304","article-title":"General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia","volume":"90","author":"Wang","year":"1993","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.11.045_bib28","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1074\/jbc.270.3.1230","article-title":"Purification and characterization of hypoxia-inducible factor 1","volume":"270","author":"Wang","year":"1995","journal-title":"The J J. Biol. Chem"},{"key":"10.1016\/j.canlet.2020.11.045_bib29","doi-asserted-by":"crossref","first-page":"21513","DOI":"10.1016\/S0021-9258(20)80571-7","article-title":"Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia","volume":"268","author":"Wang","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.11.045_bib30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nature14883","article-title":"Structural integration in hypoxia-inducible factors","volume":"524","author":"Wu","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2020.11.045_bib31","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.1128\/MCB.25.15.6415-6426.2005","article-title":"Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-inducible factor 1 alpha","volume":"25","author":"Chan","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2020.11.045_bib32","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2020.11.045_bib33","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2020.11.045_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18112495","article-title":"MicroRNAs associated with von hippel-lindau pathway in renal cell carcinoma: a comprehensive review","volume":"18","author":"Schanza","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2020.11.045_bib35","doi-asserted-by":"crossref","first-page":"14851","DOI":"10.1007\/s13277-016-5331-4","article-title":"Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature","volume":"37","author":"Slemc","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.canlet.2020.11.045_bib36","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0092-8674(02)01085-1","article-title":"Regulation and destabilization of HIF-1\u03b1 by ARD1-mediated acetylation","volume":"111","author":"Jeong","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.11.045_bib37","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1073\/pnas.082121399","article-title":"Structural basis for Hif-1 alpha\/CBP recognition in the cellular hypoxic response","volume":"99","author":"Dames","year":"2002","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.11.045_bib38","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1126\/science.1068592","article-title":"Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch","volume":"295","author":"Lando","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.canlet.2020.11.045_bib39","doi-asserted-by":"crossref","first-page":"13041","DOI":"10.1074\/jbc.M110.211110","article-title":"Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors","volume":"286","author":"Tian","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.11.045_bib40","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cmet.2018.02.020","article-title":"The factor inhibiting HIF asparaginyl hydroxylase regulates oxidative metabolism and accelerates metabolic adaptation to hypoxia","volume":"27","author":"Sim","year":"2018","journal-title":"Cell Metabol."},{"key":"10.1016\/j.canlet.2020.11.045_bib41","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.cmet.2018.02.020","article-title":"The factor inhibiting HIF asparaginyl hydroxylase regulates oxidative metabolism and accelerates metabolic adaptation to hypoxia","volume":"27","author":"Sim","year":"2018","journal-title":"Cell Metabol."},{"key":"10.1016\/j.canlet.2020.11.045_bib42","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.cmet.2010.03.001","article-title":"The asparaginyl hydroxylase factor inhibiting HIF-1alpha is an essential regulator of metabolism","volume":"11","author":"Zhang","year":"2010","journal-title":"Cell. Metabol."},{"key":"10.1016\/j.canlet.2020.11.045_bib43","doi-asserted-by":"crossref","first-page":"e86102","DOI":"10.1371\/journal.pone.0086102","article-title":"The role of factor inhibiting HIF (FIH-1) in inhibiting HIF-1 transcriptional activity in glioblastoma multiforme","volume":"9","author":"Wang","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2020.11.045_bib44","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1242\/jcs.00318","article-title":"Intracellular localisation of human HIF-1 alpha hydroxylases: implications for oxygen sensing","volume":"116","author":"Metzen","year":"2003","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2020.11.045_bib45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s13402-011-0053-5","article-title":"Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1\u03b1 expression","volume":"34","author":"Hyseni","year":"2011","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2020.11.045_bib46","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1186\/bcr1838","article-title":"Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer","volume":"9","author":"Tan","year":"2007","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib47","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jcp.22798","article-title":"Functional regulation of HIF-1\u03b1 under normoxia\u2014is there more than post-translational regulation?","volume":"227","author":"Kuschel","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2020.11.045_bib48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2020.11.045_bib49","first-page":"605","article-title":"The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells","volume":"20","author":"Zia","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.canlet.2020.11.045_bib50","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","article-title":"Mechanism of regulation of the hypoxia-inducible factor-1\u03b1 by the von Hippel-Lindau tumor suppressor protein","volume":"19","author":"Tanimoto","year":"2000","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2020.11.045_bib51","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","article-title":"HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1\u03b1 (HIF-1\u03b1) synthesis: novel mechanism for HIF-1-Mediated vascular endothelial growth factor expression","volume":"21","author":"Laughner","year":"2001","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2020.11.045_bib52","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1158\/0008-5472.CAN-04-1284","article-title":"A hypoxia-independent hypoxia-inducible factor-1 activation pathway induced by phosphatidylinositol-3 kinase\/akt in HER2 overexpressing cells","volume":"65","author":"Li","year":"2005","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib53","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3892\/ijo.2014.2367","article-title":"HIF-1alpha activation under glucose deprivation plays a central role in the acquisition of anti-apoptosis in human colon cancer cells","volume":"44","author":"Nishimoto","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2020.11.045_bib54","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-5793(02)02247-0","article-title":"Normoxic induction of the hypoxia-inducible factor 1\u03b1 by insulin and interleukin-1\u03b2 involves the phosphatidylinositol 3-kinase pathway","volume":"512","author":"Stiehl","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2020.11.045_bib55","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1091\/mbc.e02-12-0791","article-title":"Nitric oxide impairs normoxic degradation of HIF-1alpha by inhibition of prolyl hydroxylases","volume":"14","author":"Metzen","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.canlet.2020.11.045_bib56","doi-asserted-by":"crossref","first-page":"80568","DOI":"10.18632\/oncotarget.19631","article-title":"Impact of inducible nitric oxide synthase (iNOS) expression on triple negative breast cancer outcome and activation of EGFR and ERK signaling pathways","volume":"8","author":"Garrido","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.11.045_bib57","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/bjc.1995.274","article-title":"Nitric oxide synthase activity in human breast cancer","volume":"72","author":"Thomsen","year":"1995","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib58","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejca.2004.07.010","article-title":"The role of early expression of inducible nitric oxide synthase in human breast cancer","volume":"41","author":"Loibl","year":"2005","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib59","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1124\/mol.108.045278","article-title":"Nitric oxide donor, (\u00b1)-S-nitroso-N-acetylpenicillamine, stabilizes transactive hypoxia-inducible factor-1\u03b1 by inhibiting von Hippel-Lindau recruitment and asparagine hydroxylation","volume":"74","author":"Park","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2020.11.045_bib60","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cell.2013.03.004","article-title":"Influence of metabolism on epigenetics and disease","volume":"153","author":"Kaelin","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2020.11.045_bib61","doi-asserted-by":"crossref","first-page":"4675","DOI":"10.1038\/sj.onc.1209594","article-title":"Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer","volume":"25","author":"King","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.11.045_bib62","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1080\/07853890310018458","article-title":"The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase","volume":"35","author":"Pollard","year":"2003","journal-title":"Ann. Med."},{"key":"10.1016\/j.canlet.2020.11.045_bib63","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.06.017","article-title":"HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability","volume":"8","author":"Isaacs","year":"2005","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.11.045_bib64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-\u03b1 prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.11.045_bib65","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature10898","article-title":"Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation","volume":"483","author":"Koivunen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2020.11.045_bib66","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1101\/gad.217406.113","article-title":"What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer","volume":"27","author":"Losman","year":"2013","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2020.11.045_bib67","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1126\/science.1170944","article-title":"Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha","volume":"324","author":"Zhao","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.canlet.2020.11.045_bib68","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3390\/ijms20020238","article-title":"HIF-1-Dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance","volume":"20","author":"Nagao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2020.11.045_bib69","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41416-020-0886-7","article-title":"Lactate concentration in breast cancer using advanced magnetic resonance spectroscopy","volume":"123","author":"Cheung","year":"2020","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12885-019-5503-x","article-title":"Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels","volume":"19","author":"Campbell","year":"2019","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib71","doi-asserted-by":"crossref","first-page":"32043","DOI":"10.18632\/oncotarget.16761","article-title":"Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.11.045_bib72","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.molcel.2007.10.035","article-title":"FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2","volume":"28","author":"Bakker","year":"2007","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2020.11.045_bib73","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10571-012-9803-9","article-title":"Hypoxia inducible factor-1: its potential role in cerebral ischemia","volume":"32","author":"Singh","year":"2012","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.canlet.2020.11.045_bib74","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.biocel.2013.07.025","article-title":"Cobalt stimulates HIF-1-dependent but inhibits HIF-2-dependent gene expression in liver cancer cells","volume":"45","author":"Befani","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.canlet.2020.11.045_bib75","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbrc.2006.02.116","article-title":"Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway","volume":"343","author":"Woo","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2020.11.045_bib76","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11373-004-8177-5","article-title":"Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma","volume":"12","author":"Huang","year":"2005","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.canlet.2020.11.045_bib77","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/annonc\/mdu090","article-title":"Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy","volume":"25","author":"Bane","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2020.11.045_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172911","article-title":"PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer","volume":"12","author":"Gschwantler-Kaulich","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2020.11.045_bib79","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.3390\/ijms21165760","article-title":"The importance of breast adipose tissue in breast cancer","volume":"21","author":"Kothari","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2020.11.045_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00040","article-title":"Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironment","volume":"9","author":"Sormendi","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2020.11.045_bib81","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2015.06.005","article-title":"Hypoxia inducible factor-1alpha: its role in colorectal carcinogenesis and metastasis","volume":"366","author":"Nagaraju","year":"2015","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.11.045_bib82","doi-asserted-by":"crossref","first-page":"e90678","DOI":"10.1371\/journal.pone.0090678","article-title":"HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy","volume":"9","author":"Chen","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.canlet.2020.11.045_bib83","doi-asserted-by":"crossref","first-page":"R191","DOI":"10.1186\/bcr775","article-title":"Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?","volume":"6","author":"Gruber","year":"2004","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib84","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13018-019-1101-5","article-title":"Clinicopathological and prognostic value of hypoxia-inducible factor-1\u03b1 in patients with bone tumor: a systematic review and meta-analysis","volume":"14","author":"Luo","year":"2019","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib85","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.3748\/wjg.v24.i22.2381","article-title":"Prognostic value of hypoxia-inducible factor-1 alpha and prolyl 4-hydroxylase beta polypeptide overexpression in gastric cancer","volume":"24","author":"Zhang","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canlet.2020.11.045_bib86","doi-asserted-by":"crossref","first-page":"24218","DOI":"10.1074\/jbc.M313599200","article-title":"The stem cell marker Bcrp\/ABCG2 enhances hypoxic cell survival through interactions with heme","volume":"279","author":"Krishnamurthy","year":"2004","journal-title":"T J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.11.045_bib87","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2147\/OTT.S82835","article-title":"Hypoxia-inducible factor-1\u03b1 induces multidrug resistance protein in colon cancer","volume":"8","author":"Lv","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2020.11.045_bib88","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0091270007311568","article-title":"P-glycoprotein: so many ways to turn it on","volume":"48","author":"Callaghan","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.canlet.2020.11.045_bib89","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/jnci\/89.13.917","article-title":"Multidrug resistance in breast cancer: a meta-analysis of MDR1\/gp170 expression and its possible functional significance","volume":"89","author":"Trock","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2020.11.045_bib90","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenetics Genom."},{"key":"10.1016\/j.canlet.2020.11.045_bib91","doi-asserted-by":"crossref","first-page":"E5429","DOI":"10.1073\/pnas.1421438111","article-title":"Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells","volume":"111","author":"Samanta","year":"2014","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.11.045_bib92","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2407-12-4","article-title":"HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: a potential model of the chemo-resistance of invasive micropapillary carcinoma of the breast","volume":"12","author":"Doublier","year":"2012","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib93","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1476-4598-9-191","article-title":"Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia","volume":"9","author":"Flamant","year":"2010","journal-title":"Mol. Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib94","doi-asserted-by":"crossref","first-page":"30880","DOI":"10.1074\/jbc.R114.609248","article-title":"Multidrug resistance protein 1 (MRP1, ABCC1), a \"multitasking\" ATP-binding cassette (ABC) transporter","volume":"289","author":"Cole","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2020.11.045_bib95","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.febslet.2005.12.036","article-title":"Substrate recognition and transport by multidrug resistance protein 1 (ABCC1)","volume":"580","author":"Deeley","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.canlet.2020.11.045_bib96","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1179\/joc.2008.20.6.734","article-title":"Role of ABCB1 and ABCC1 gene induction on survival in locally advanced breast cancer","volume":"20","author":"Atalay","year":"2008","journal-title":"J. Chemother."},{"key":"10.1016\/j.canlet.2020.11.045_bib97","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/15384047.2016.1139228","article-title":"Hypoxia regulates ABCG2 activity through the activation of ERK1\/2\/HIF-1\u03b1 and contributes to chemoresistance in pancreatic cancer cells","volume":"17","author":"He","year":"2016","journal-title":"Canc. Biol. Ther."},{"key":"10.1016\/j.canlet.2020.11.045_bib98","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00280-008-0838-z","article-title":"Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer","volume":"63","author":"Yuan","year":"2009","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2020.11.045_bib99","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","article-title":"Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport--an update","volume":"17","author":"Mao","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.canlet.2020.11.045_bib100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13046-015-0275-x","article-title":"New trends for overcoming ABCG2\/BCRP-mediated resistance to cancer therapies","volume":"34","author":"Westover","year":"2015","journal-title":"J. Exp. Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib101","doi-asserted-by":"crossref","first-page":"e814s","DOI":"10.6061\/clinics\/2018\/e814s","article-title":"Autophagy and intermittent fasting: the connection for cancer therapy?","volume":"73","author":"Antunes","year":"2018","journal-title":"Clinics"},{"key":"10.1016\/j.canlet.2020.11.045_bib102","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/15548627.2017.1378838","article-title":"Autophagy pathway: cellular and molecular mechanisms","volume":"14","author":"Yu","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2020.11.045_bib103","first-page":"52","article-title":"Autophagy and multidrug resistance in cancer","volume":"36","author":"Li","year":"2017","journal-title":"Chin. J. Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib104","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/path.5222","article-title":"Autophagy, cancer stem cells and drug resistance","volume":"247","author":"Smith","year":"2019","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2020.11.045_bib105","doi-asserted-by":"crossref","first-page":"109415","DOI":"10.1016\/j.biopha.2019.109415","article-title":"Autophagy: a novel mechanism of chemoresistance in cancers","volume":"119","author":"Li","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2020.11.045_bib106","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.canlet.2019.10.030","article-title":"EGFR-mediated autophagy in tumourigenesis and therapeutic resistance","volume":"469","author":"Wu","year":"2020","journal-title":"Canc. Lett."},{"key":"10.1016\/j.canlet.2020.11.045_bib107","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1080\/15548627.2018.1450020","article-title":"Mechanisms and context underlying the role of autophagy in cancer metastasis","volume":"14","author":"Dower","year":"2018","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2020.11.045_bib108","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41598-020-58482-w","article-title":"Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors induce autophagy and have a protective effect in an in-vitro ischaemia model","volume":"10","author":"Singh","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2020.11.045_bib109","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.4161\/auto.5.8.9996","article-title":"Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells","volume":"5","author":"Song","year":"2009","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2020.11.045_bib110","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12931-015-0285-4","article-title":"Autophagy contributes to the chemo-resistance of non-small cell lung cancer in hypoxic conditions","volume":"16","author":"Lee","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib111","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1080\/15548627.2019.1687213","article-title":"Hypoxia-induced autophagy drives colorectal cancer initiation and progression by activating the PRKC\/PKC-EZR (ezrin) pathway","volume":"16","author":"Qureshi-Baig","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.canlet.2020.11.045_bib112","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1111\/jcmm.14896","article-title":"PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation","volume":"24","author":"Ma","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.canlet.2020.11.045_bib113","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1038\/onc.2009.228","article-title":"The HIF1alpha-inducible pro-cell death gene BNIP3 is a novel target of SIM2s repression through cross-talk on the hypoxia response element","volume":"28","author":"Farrall","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2020.11.045_bib114","first-page":"2066","article-title":"The correlation between autophagy and tamoxifen resistance in breast cancer","volume":"12","author":"Liu","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.canlet.2020.11.045_bib115","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1586\/era.11.111","article-title":"Autophagy and endocrine resistance in breast cancer","volume":"11","author":"Cook","year":"2011","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2020.11.045_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0000000000000572","article-title":"Autophagy and doxorubicin resistance in cancer","volume":"29","author":"Chen","year":"2018","journal-title":"Anti Canc. Drugs"},{"key":"10.1016\/j.canlet.2020.11.045_bib117","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10549-015-3283-9","article-title":"Autophagy inhibition re-sensitizes pulse stimulation-selected paclitaxel-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis","volume":"149","author":"Wen","year":"2015","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.canlet.2020.11.045_bib118","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00280-017-3298-5","article-title":"Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity","volume":"79","author":"Tan","year":"2017","journal-title":"Canc. Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2020.11.045_bib119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006251","article-title":"Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab","volume":"4","author":"Vazquez-Martin","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2020.11.045_bib120","doi-asserted-by":"crossref","first-page":"15916","DOI":"10.1038\/ncomms15916","article-title":"CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers","volume":"8","author":"Vijayaraghavan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2020.11.045_bib121","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1152\/physiol.00016.2013","article-title":"Apoptotic cell death under hypoxia","volume":"29","author":"Sendoel","year":"2014","journal-title":"Physiol."},{"key":"10.1016\/j.canlet.2020.11.045_bib122","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.molcel.2010.11.035","article-title":"The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose","volume":"40","author":"Lowman","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2020.11.045_bib123","doi-asserted-by":"crossref","first-page":"R450","DOI":"10.1186\/bcr813","article-title":"Expression of hypoxia-inducible factor-1alpha and cell cycle proteins in invasive breast cancer are estrogen receptor related","volume":"6","author":"Bos","year":"2004","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047519","article-title":"Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types","volume":"7","author":"Sermeus","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2020.11.045_bib125","doi-asserted-by":"crossref","first-page":"10212","DOI":"10.1093\/nar\/gkz766","article-title":"HIF-transcribed p53 chaperones HIF-1\u03b1","volume":"47","author":"Madan","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib126","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.14.1.34","article-title":"Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha","volume":"14","author":"Ravi","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2020.11.045_bib127","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/jcp.21980","article-title":"PKB\/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2","volume":"222","author":"Choy","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2020.11.045_bib128","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/379088a0","article-title":"Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours","volume":"379","author":"Graeber","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2020.11.045_bib129","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.bbrc.2006.02.094","article-title":"Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate","volume":"342","author":"Li","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2020.11.045_bib130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1186\/1471-2407-12-391","article-title":"TMEM45A is essential for hypoxia-induced chemoresistance in breast and liver cancer cells","volume":"12","author":"Flamant","year":"2012","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2020.11.045_bib131","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3389\/fonc.2020.00299","article-title":"Editorial: the role of breast cancer stem cells in clinical outcomes","volume":"10","author":"Raman","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2020.11.045_bib132","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2020.11.045_bib133","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.pharmthera.2016.02.008","article-title":"Cancer stem cells and chemoresistance: the smartest survives the raid","volume":"160","author":"Zhao","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2020.11.045_bib134","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1158\/0008-5472.CAN-10-3320","article-title":"HIF induces human embryonic stem cell markers in cancer cells","volume":"71","author":"Mathieu","year":"2011","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib135","doi-asserted-by":"crossref","first-page":"E5429","DOI":"10.1073\/pnas.1421438111","article-title":"Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells","volume":"111","author":"Samanta","year":"2014","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.11.045_bib136","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","article-title":"Targeting metabolism for cancer therapy","volume":"24","author":"Luengo","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.canlet.2020.11.045_bib137","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.bbabio.2017.02.005","article-title":"Drug discovery strategies in the field of tumor energy metabolism: limitations by metabolic flexibility and metabolic resistance to chemotherapy","volume":"1858","author":"Amoedo","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2020.11.045_bib138","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/0008-5472.CAN-11-0127","article-title":"Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism","volume":"71","author":"Zhao","year":"2011","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib139","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/0008-5472.CAN-17-2906","article-title":"Transketolase regulates the metabolic switch to control breast cancer cell metastasis via the \u03b1-ketoglutarate signaling pathway","volume":"78","author":"Tseng","year":"2018","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib140","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3389\/fonc.2020.00428","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2020.11.045_bib141","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1172\/JCI67230","article-title":"HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations","volume":"123","author":"Semenza","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2020.11.045_bib142","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41418-019-0292-y","article-title":"Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications","volume":"26","author":"Nazio","year":"2019","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2020.11.045_bib143","doi-asserted-by":"crossref","first-page":"17910","DOI":"10.1073\/pnas.0909353106","article-title":"Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization","volume":"106","author":"Lee","year":"2009","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.11.045_bib144","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1158\/1535-7163.MCT-08-0074","article-title":"A novel mode of action of YC-1 in HIF inhibition: stimulation of FIH-dependent p300 dissociation from HIF-1{alpha}","volume":"7","author":"Li","year":"2008","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2020.11.045_bib145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccr.2004.06.009","article-title":"Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway","volume":"6","author":"Kung","year":"2004","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2020.11.045_bib146","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2007-11-120576","article-title":"Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1","volume":"111","author":"Shin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2020.11.045_bib147","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/cb700110z","article-title":"Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface","volume":"2","author":"Nickols","year":"2007","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.canlet.2020.11.045_bib148","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.4161\/cc.5.16.3019","article-title":"Targeting the PAS-A domain of HIF-1alpha for development of small molecule inhibitors of HIF-1","volume":"5","author":"Park","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2020.11.045_bib149","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1021\/acs.jmedchem.8b01596","article-title":"Small-molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications","volume":"62","author":"Li","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2020.11.045_bib150","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3349\/ymj.2017.58.3.489","article-title":"Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy","volume":"58","author":"Yu","year":"2017","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.canlet.2020.11.045_bib151","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-019-0752-z","article-title":"HIF inhibitors: status of current clinical development","volume":"21","author":"Fallah","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.canlet.2020.11.045_bib152","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-pharmtox-010818-021637","article-title":"Pharmacologic targeting of hypoxia-inducible factors","volume":"59","author":"Semenza","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.canlet.2020.11.045_bib153","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10637-010-9455-x","article-title":"A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal\u00ae dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)","volume":"29","author":"Harrison","year":"2011","journal-title":"Investig. N. Drugs"},{"key":"10.1016\/j.canlet.2020.11.045_bib154","doi-asserted-by":"crossref","first-page":"7940","DOI":"10.1158\/1078-0432.CCR-08-0221","article-title":"A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer","volume":"14","author":"Heath","year":"2008","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib155","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10637-006-9208-z","article-title":"A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma","volume":"24","author":"Ronnen","year":"2006","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.canlet.2020.11.045_bib156","doi-asserted-by":"crossref","first-page":"TPS1144","DOI":"10.1200\/jco.2013.31.15_suppl.tps1144","article-title":"Digoxin as an inhibitor of global hypoxia inducible factor-1\u03b1 (HIF1\u03b1) expression and downstream targets in breast cancer: dig-HIF1 pharmacodynamic trial","volume":"31","author":"Bardia","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2020.11.045_bib157","doi-asserted-by":"crossref","first-page":"113922","DOI":"10.1016\/j.bcp.2020.113922","article-title":"HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo","volume":"175","author":"Kachamakova-Trojanowska","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.canlet.2020.11.045_bib158","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3727\/096504014X13983417587366","article-title":"HIF-1 dimerization inhibitor acriflavine enhances antitumor activity of sunitinib in breast cancer model","volume":"22","author":"Yin","year":"2014","journal-title":"Oncol. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib159","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/bph.12438","article-title":"Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors","volume":"171","author":"Ahmadi","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.canlet.2020.11.045_bib160","first-page":"73","article-title":"Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells","volume":"41","author":"Teicher","year":"1981","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib161","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s42255-019-0045-8","article-title":"Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy","volume":"1","author":"Ye","year":"2019","journal-title":"Nat. Metabol."},{"key":"10.1016\/j.canlet.2020.11.045_bib162","first-page":"178","article-title":"Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxiainducible factor 1alphamediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation","volume":"41","author":"Valencia-Cervantes","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2020.11.045_bib163","first-page":"2241","article-title":"Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells","volume":"5","author":"Hussein","year":"2006","journal-title":"Mol. Canc. Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib164","doi-asserted-by":"crossref","first-page":"8648","DOI":"10.18632\/oncotarget.3257","article-title":"Basal and therapy-driven hypoxia-inducible factor-1\u03b1 confers resistance to endocrine therapy in estrogen receptor-positive breast cancer","volume":"6","author":"Jia","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2020.11.045_bib165","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/bcr3609","article-title":"Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer","volume":"16","author":"Kazi","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.canlet.2020.11.045_bib166","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1631\/jzus.B1600266","article-title":"Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1\u03b1","volume":"17","author":"Shan","year":"2016","journal-title":"J. Zhejiang Univ. - Sci. B"},{"key":"10.1016\/j.canlet.2020.11.045_bib167","doi-asserted-by":"crossref","first-page":"e1367","DOI":"10.1038\/cddis.2014.297","article-title":"Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-alpha-mediated signaling","volume":"5","author":"Peng","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2020.11.045_bib168","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1073\/pnas.1422015112","article-title":"Estrogen receptor-\u03b1 directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer","volume":"112","author":"Yang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.canlet.2020.11.045_bib169","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.bbagen.2017.05.009","article-title":"Activation of STAT3\/HIF-1alpha\/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN","volume":"1861","author":"Aghazadeh","year":"2017","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2020.11.045_bib170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238.2013.838205","article-title":"Transcriptional regulation by hypoxia inducible factors","volume":"49","author":"Dengler","year":"2014","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.canlet.2020.11.045_bib171","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.pharmthera.2016.04.009","article-title":"Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer","volume":"164","author":"Wigerup","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2020.11.045_bib172","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520306431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383520306431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:55:27Z","timestamp":1759593327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383520306431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":172,"alternative-id":["S0304383520306431"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2020.11.045","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoxia-mediated drug resistance in breast cancers","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2020.11.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}